188 related articles for article (PubMed ID: 16243963)
1. In vivo cardiac electrophysiologic effects of a novel diphenylphosphine oxide IKur blocker, (2-Isopropyl-5-methylcyclohexyl) diphenylphosphine oxide, in rat and nonhuman primate.
Regan CP; Wallace AA; Cresswell HK; Atkins CL; Lynch JJ
J Pharmacol Exp Ther; 2006 Feb; 316(2):727-32. PubMed ID: 16243963
[TBL] [Abstract][Full Text] [Related]
2. In vivo antiarrhythmic and cardiac electrophysiologic effects of a novel diphenylphosphine oxide IKur blocker (2-isopropyl-5-methylcyclohexyl) diphenylphosphine oxide.
Stump GL; Wallace AA; Regan CP; Lynch JJ
J Pharmacol Exp Ther; 2005 Dec; 315(3):1362-7. PubMed ID: 16157659
[TBL] [Abstract][Full Text] [Related]
3. Electrophysiological and antiarrhythmic effects of the novel I(Kur) channel blockers, S9947 and S20951, on left vs. right pig atrium in vivo in comparison with the I(Kr) blockers dofetilide, azimilide, d,l-sotalol and ibutilide.
Knobloch K; Brendel J; Peukert S; Rosenstein B; Busch AE; Wirth KJ
Naunyn Schmiedebergs Arch Pharmacol; 2002 Nov; 366(5):482-7. PubMed ID: 12382079
[TBL] [Abstract][Full Text] [Related]
4. Novel, potent inhibitors of human Kv1.5 K+ channels and ultrarapidly activating delayed rectifier potassium current.
Lagrutta A; Wang J; Fermini B; Salata JJ
J Pharmacol Exp Ther; 2006 Jun; 317(3):1054-63. PubMed ID: 16522807
[TBL] [Abstract][Full Text] [Related]
5. In vivo cardiac electrophysiologic and antiarrhythmic effects of an isoquinoline IKur blocker, ISQ-1, in rat, dog, and nonhuman primate.
Regan CP; Stump GL; Wallace AA; Anderson KD; McIntyre CJ; Liverton NJ; Lynch JJ
J Cardiovasc Pharmacol; 2007 Apr; 49(4):236-45. PubMed ID: 17438409
[TBL] [Abstract][Full Text] [Related]
6. Characterization of a novel Kv1.5 channel blocker in Xenopus oocytes, CHO cells, human and rat cardiomyocytes.
Bachmann A; Gutcher I; Kopp K; Brendel J; Bosch RF; Busch AE; Gögelein H
Naunyn Schmiedebergs Arch Pharmacol; 2001 Nov; 364(5):472-8. PubMed ID: 11692231
[TBL] [Abstract][Full Text] [Related]
7. Is there a functional correlate of Kv1.5 in the ventricle of canine heart and what would it mean for the use of I(Kur) blockers?
Wettwer E
Br J Pharmacol; 2007 Nov; 152(6):835-7. PubMed ID: 17876301
[TBL] [Abstract][Full Text] [Related]
8. High-throughput analysis of drug binding interactions for the human cardiac channel, Kv1.5.
Karczewski J; Kiss L; Kane SA; Koblan KS; Lynch RJ; Spencer RH
Biochem Pharmacol; 2009 Jan; 77(2):177-85. PubMed ID: 18955031
[TBL] [Abstract][Full Text] [Related]
9. Atrial antifibrillatory effects of structurally distinct IKur blockers 3-[(dimethylamino)methyl]-6-methoxy-2-methyl-4-phenylisoquinolin-1(2H)-one and 2-phenyl-1,1-dipyridin-3-yl-2-pyrrolidin-1-yl-ethanol in dogs with underlying heart failure.
Regan CP; Kiss L; Stump GL; McIntyre CJ; Beshore DC; Liverton NJ; Dinsmore CJ; Lynch JJ
J Pharmacol Exp Ther; 2008 Jan; 324(1):322-30. PubMed ID: 17967939
[TBL] [Abstract][Full Text] [Related]
10. Molecular determinants of Kv1.5 channel block by diphenyl phosphine oxide-1.
Du YM; Zhang XX; Tu DN; Zhao N; Liu YJ; Xiao H; Sanguinetti MC; Zou A; Liao YH
J Mol Cell Cardiol; 2010 Jun; 48(6):1111-20. PubMed ID: 20184887
[TBL] [Abstract][Full Text] [Related]
11. New drugs targeting the cardiac ultra-rapid delayed-rectifier current (I Kur): rationale, pharmacology and evidence for potential therapeutic value.
Ford JW; Milnes JT
J Cardiovasc Pharmacol; 2008 Aug; 52(2):105-20. PubMed ID: 18670369
[TBL] [Abstract][Full Text] [Related]
12. Cardiac electrophysiologic and antiarrhythmic actions of 3,4-dihydro-1'-[2-(benzofurazan-5-yl) ethyl]-6-methanesulfonamidospiro [(2H)-1-benzopyran-2,4'-piperidin]-4-one HCl (L-691,121), a novel class III agent.
Lynch JJ; Wallace AA; Van der Gaag LH; Baskin EP; Bear CM; Gehret JR; Kothstein T; Stupienski RF; Appleby SD; Sanguinetti MC
J Pharmacol Exp Ther; 1993 May; 265(2):720-30. PubMed ID: 8496818
[TBL] [Abstract][Full Text] [Related]
13. MK-0448, a specific Kv1.5 inhibitor: safety, pharmacokinetics, and pharmacodynamic electrophysiology in experimental animal models and humans.
Pavri BB; Greenberg HE; Kraft WK; Lazarus N; Lynch JJ; Salata JJ; Bilodeau MT; Regan CP; Stump G; Fan L; Mehta A; Wagner JA; Gutstein DE; Bloomfield D
Circ Arrhythm Electrophysiol; 2012 Dec; 5(6):1193-201. PubMed ID: 23060423
[TBL] [Abstract][Full Text] [Related]
14. AVE0118, blocker of the transient outward current (I(to)) and ultrarapid delayed rectifier current (I(Kur)), fully restores atrial contractility after cardioversion of atrial fibrillation in the goat.
de Haan S; Greiser M; Harks E; Blaauw Y; van Hunnik A; Verheule S; Allessie M; Schotten U
Circulation; 2006 Sep; 114(12):1234-42. PubMed ID: 16940189
[TBL] [Abstract][Full Text] [Related]
15. Electrophysiological characterization and antiarrhythmic efficacy of the mixed potassium channel-blocking antiarrhythmic agent AZ13395438 in vitro and in vivo.
Jacobson I; Duker G; Florentzson M; Linhardt G; Lindhardt E; Nordkam AK; Åstrand A; Carlsson L
J Cardiovasc Pharmacol Ther; 2013 May; 18(3):290-300. PubMed ID: 23307834
[TBL] [Abstract][Full Text] [Related]
16. In silico study on the effects of IKur block kinetics on prolongation of human action potential after atrial fibrillation-induced electrical remodeling.
Tsujimae K; Murakami S; Kurachi Y
Am J Physiol Heart Circ Physiol; 2008 Feb; 294(2):H793-800. PubMed ID: 18055524
[TBL] [Abstract][Full Text] [Related]
17. Membrane cholesterol modulates Kv1.5 potassium channel distribution and function in rat cardiomyocytes.
Abi-Char J; Maguy A; Coulombe A; Balse E; Ratajczak P; Samuel JL; Nattel S; Hatem SN
J Physiol; 2007 Aug; 582(Pt 3):1205-17. PubMed ID: 17525113
[TBL] [Abstract][Full Text] [Related]
18. Antifibrillatory agents and potassium channels in the atria: pore block versus channel trafficking.
McEwen DP; Martens JR
Mol Interv; 2009 Apr; 9(2):79-86. PubMed ID: 19401540
[TBL] [Abstract][Full Text] [Related]
19. RSD1000: a novel antiarrhythmic agent with increased potency under acidic and high-potassium conditions.
Yong SL; Xu R; McLarnon JG; Zolotoy AB; Beatch GN; Walker MJ
J Pharmacol Exp Ther; 1999 Apr; 289(1):236-44. PubMed ID: 10087010
[TBL] [Abstract][Full Text] [Related]
20. Effects of flecainide on atrial and ventricular refractoriness in rabbits in vitro and in vivo.
Leung MW; Chan AP; So PP; Lowe GC; Guppy LJ; Walker MJ
Proc West Pharmacol Soc; 2004; 47():42-5. PubMed ID: 15633609
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
